drugset
drugset / Trial / NCT00479076

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

NCT00479076 ↗

Phase 1 Completed 22 enrolled Sanofi Regeneron Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the recommended phase II dose of AVE0005 in combination with S-1 in Japanese cancer patients. The secondary objectives of this study are to assess the safety profile of AVE0005, to determine the pharmacokinetics of AVE0005, to make a preliminary assessment of antitumor effects.

Timeline

Start
2007-03
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic — Intravenous
Background S-1 Small molecule — Oral

Indications

neoplasm